Genetically transformed world records: A reality or in the sphere of fantasy?

Medical Science Monitor

Volumn 15, Issue 2, 2009, Pages

  Gatzidou, Elisavet ^a   Gatzidou, Georgia ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ethical issues; Gene doping; Polymorphisms

Indexed keywords

ALPHA ACTININ 3; ANGIOMATRIX INTEGRIN BINDING PROTEIN; BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; DYNORPHIN; ENDORPHIN; ENKEPHALIN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; FOLLISTATIN; GLUTAMATE DECARBOXYLASE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH DIFFERENTIATION FACTOR 1; GROWTH FACTOR; HUMAN GROWTH HORMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 3; INTERLEUKIN 4; MYOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PROOPIOMELANOCORTIN; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LEUKEMIA; ANEMIA; ANGINA PECTORIS; ARTERY DISEASE; ATHLETE; ATHLETIC PERFORMANCE; CACHEXIA; CARTILAGE INJURY; CHRONIC KIDNEY FAILURE; CHRONIC PAIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DNA SPLICING; DRUG ABUSE; DYSLIPIDEMIA; ENDURANCE; ETHICS; FRACTURE HEALING; FUSION GENE; GENE DOPING; GENE EXPRESSION; GENE INSERTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC ENHANCEMENT; GENETIC POLYMORPHISM; GENETIC RISK; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN GENOME; KIDNEY FAILURE; LIGAMENT RUPTURE; MALPRACTICE; MITOCHONDRIAL GENE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE HYPOTROPHY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; NEOPLASM; NEUTROPENIA; NONHUMAN; NUTRIGENOMICS; OBESITY; PHARMACOGENETICS; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SPORT; TENDON RUPTURE; TRANSGENE; DOPING; GENETIC TRANSFORMATION;

ATHLETIC PERFORMANCE; DOPING IN SPORTS; GENE THERAPY; HUMANS; POLYMORPHISM, GENETIC; TRANSFORMATION, GENETIC;

EID: 63449125155     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Patil SD, Rhodes DG, Burgess DJ: DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J, 2005;7: E61-77
2. Strachan T, Read AP: Gene therapy and other molecular genetic- based therapeutic approaches In: Strachan T, Read AP (eds.); Human Molecular Genetics. Oxford: Bios Scientific Publishers Ltd., 2000; 515-39
3. WADA: The world anti - doping code. The 2006 prohibited list. International standard. Keynote address WADA health medical and research committee. 1-1-2005 Montreal: WADA, 2005
4. Schjerling P: Gene doping. Scand J Med Sci Sports, 2008; 18: 121-22
5. Baoutina A, Alexander IE, Rasko JE, Emslie KR: Developing strategies for detection of gene doping. J Gene Med, 2008; 10: 3-20
6. Minunni M, Scarano S, Mascini M: Affinity-based biosensors as promising tools for gene doping detection. Trends Biotechnol, 2008; 26: 236-43
7. Trent RJ, Alexander IE: Gene therapy in sport. Br J Sports Med, 2006; 40: 4-5
8. Haisma HJ, de Hon O: Gene doping. Int J Sports Med, 2006; 27: 257-66
9. Sinn PL, Sauter SL, McCray PB Jr: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther, 2005; 12: 1089-98
10. Gersbach CA, Guldberg RE, Garcia AJ: In vitro and in vivo osteoblastic differentiation of BMP-2 and Runx2-engineered skeletal myoblasts. J Cell Biochem, 2007; 100: 1324-36
11. Menezes KM, Mok HS, Barry MA: Increased transduction of skeletal muscle cells by fibroblast growth factor - modified adenoviral vectors. Hum Gene Ther, 2006; 17: 314-20
12. Zoltick PW, Chirmule N, Schnell MA et al: Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol, 2001; 75: 5222-29
13. Oh TK, Quan GH, Kim HY et al: Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol, 2006; 26: 326-34
14. Seppen J, Barry SC, Harder B, OsborneWR: Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood, 2001; 98: 594-96
15. Huard J, Krisky D, Oligino T et al: Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord, 1997; 7: 299-313
16. Chirmule N, Xiao W, Truneh A et al: Humoral immunity to adeno-asso- ciated virus type 2 vectors following administration to murine and non-human primate muscle. J Virol, 2000; 74: 2420-25
17. Barton-Davis ER, Shoturma DI, Musaro A et al: Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA, 1998; 95: 15603-7
18. Wolff JA, Malone RW, Williams P et al: Direct gene transfer into mouse muscle in vivo. Science, 1990; 247: 1465-68
19. Dai Q, Huang J, Klitzman B et al: Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation, 2004; 110: 2467-75
20. McMahon JM, Wells DJ: Electroporation for gene transfer to skeletal muscles: current status. Bio Drugs, 2004; 18: 155-65
21. Mir LM, Moller PH, Andre F, Gehl J: Electric pulse-mediated gene delivery to various animal tissues. Adv Genet, 2005; 54: 83-114
22. Wells DJ: Gene doping: the hype and the reality. Br J Pharamacol, 2008; 154: 623-31
23. Cousin J: Breakthrough of the year. Small RNAs make big splash. Science, 2002; 298: 2296-97
24. Fedoruk MN, Rupert JL: Myostatin inhibition: a potential performance enhancement strategy? Scand J Med Sci Sports, 2008; 18: 123-31
25. Tsuchida K: Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel, 2008; 11: 487-94
26. Acosta J, Carpio Y, Borroto I et al: Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol, 2005; 119: 324-31
27. Magee TR, Artaza JN, Ferrini MG et al: Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med, 2006; 8: 1171-81
28. Sweeney HL: Gene Doping. Sci Am, 2004; 291: 62-69
29. Baoutina A, Alexander IE, Rasko JE, Emslie KR: Potential use of gene transfer in athletic performance enhancement. Mol Ther, 2007; 15: 1751-66
30. Lippi G, Guidi G: New scenarios in antidoping research. Clin Chem, 2003; 49: 2106-7
31. MacArthur DG, North KN: Genes and human elite athletic performance. Hum Genet, 2005; 116: 331-39
32. Rankinen T, Bray MS, Hagberg JM et al: The human gene map for performance and health-related fitness phenotypes: the 2005 update. Med Sci Sports Exerc, 2006; 38: 1863-88
33. He Z, Hu Y, Feng L et al: Polymorphisms in the HBB gene relate to individual cardiorespiratory adaptation in response to endurance training. Br J Sports Med, 2006; 40: 998-1002
34. Prior SJ, Hagberg JM, Paton CM et al: DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol, 2006; 290: H1848-55
35. Walsh S, Metter EJ, Ferrucci L, Roth SM: Activin-type II receptor B (ACVR2B) and follistatin haplotype associations with muscle mass and strength in humans. J Appl Physiol, 2007; 102: 2142-48
36. Wolfarth B, Rankinen T, Muhlbauer S et al: Association between a beta2- adrenergic receptor polymorphism and elite endurance performance. Metabolism, 2007; 56: 1649-51
37. Yang N, MacArthur DG, Wolde B et al: The ACTN3 R577X polymorphism in East and West African athletes. Med Sci Sports Exerc, 2007; 39: 1985-88
38. McCrory P: Super athletes or gene cheats? Br J Sports Med, 2003; 37: 192-93
39. Sharp NC: The human genome and sport, including epigenetics and athleticogenomics: A brief look at a rapidly changing field. J Sports Sci, 2008; 10: 1-7
40. Evans WE, McLeod HL: Pharmacogenomics-drugs disposition, drug targets, and side effects. N Engl J Med, 2003; 348: 538-49
41. Weinshilboum R: Inheritance and drug response. N Engl J Med, 2003; 348: 529-37
42. Ordovas JM, Mooser V: Nutrigenomics and nutrigenetics. Curr Opin Lipidol, 2004; 15: 101-8
43. Fontaine-Bisson B, Wolever TM, Chiasson JL et al: Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations. Am J Clin Nutr, 2007; 86: 768-74
44. Lovegrove JA, Gitau R: Personalized nutrition for the prevention of cardiovascular disease: a future perspective. J Hum Nutr Diet, 2008; 21: 306-16
45. Raper SE, Chirmule N, Lee FS et al: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 2003; 80: 148-58
46. Hacein-Bey-Abina S, Le Deist F, Carlier F et al: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med, 2002; 346: 1185-93
47. Azzazy HM, Mansour MM, Christenson RH: Doping in the recombinant era: Strategies and counterstrategies. Clin Biochem, 2005; 38: 959-65
48. Gao G, Lebherz C, Weiner DJ et al: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004; 103: 3300-2
49. Palmer DH, Mautner V, Mirza D et al: Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adeno- virus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol, 2004; 22: 1546-52
50. Vogel G: A race to the starting line. Science, 2004; 305: 632-35
51. High K Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? J Thromb Haemost, 2005; 3: 1682-91
52. Arruda VR, Fields PA, Milner R et al: Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther, 2001; 4: 586-92
53. Tenenbaum L, Lehtonen E, Monahan PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther, 2003; 3: 545-65
54. Friedman T, Schneider AJ: Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet, 2006; 51: 1-9
55. Miah A: Rethinking enhancement in sport. Ann NY Acad Sci, 2006; 1093: 301-20
56. DeFrancesco L: The faking of champions. Nat Biotechnol, 2004; 22: 1069-71
57. Unal M, Ozer Unal D: Gene doping in sports. Sports Med, 2004; 34: 357-62
58. Azzazy HM, Mansour MM: Rogue athletes and recombinant DNA technology: challenges for doping control. Analyst, 2007; 132: 951-57